share_log

Talaris Therapeutics Analyst Ratings

Talaris Therapeutics Analyst Ratings

塔拉里斯治療分析師評級
Benzinga Analyst Ratings ·  2023/01/30 06:12
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
01/30/2023 795.52% HC Wainwright & Co. → $12 Reiterates → Buy
10/24/2022 795.52% HC Wainwright & Co. $18 → $12 Maintains Buy
10/20/2022 49.25% SVB Leerink $7 → $2 Maintains Market Perform
10/20/2022 1243.28% HC Wainwright & Co. → $18 Initiates Coverage On → Buy
09/09/2022 347.76% Morgan Stanley $8 → $6 Maintains Equal-Weight
07/05/2022 497.01% Morgan Stanley → $8 Downgrades Overweight → Equal-Weight
07/01/2022 422.39% SVB Leerink $21 → $7 Downgrades Outperform → Market Perform
05/24/2022 1392.54% Morgan Stanley $21 → $20 Maintains Overweight
05/13/2022 1467.16% SVB Leerink $22 → $21 Maintains Outperform
03/23/2022 1467.16% Morgan Stanley $20 → $21 Maintains Overweight
11/12/2021 1541.79% SVB Leerink $21 → $22 Maintains Outperform
06/01/2021 2511.94% Morgan Stanley → $35 Initiates Coverage On → Overweight
06/01/2021 1840.3% Guggenheim → $26 Initiates Coverage On → Buy
06/01/2021 2511.94% Evercore ISI Group → $35 Initiates Coverage On → Outperform
06/01/2021 1467.16% SVB Leerink → $21 Initiates Coverage On → Outperform
日期 上行/下行 分析公司 目標價格變化 評級變化 上一次/當前評級
2023年1月30日 795.52% HC Wainwright公司 →$12 重申 →購買
10/24/2022 795.52% HC Wainwright公司 $18→$12 維護 買
10/20/2022 49.25% SVB Leerink $7→$2 維護 市場表現
10/20/2022 1243.28% HC Wainwright公司 →$18 開始承保 →購買
09/09/2022 347.76% 摩根士丹利 $8→$6 維護 等重
07/05/2022 497.01% 摩根士丹利 →$8 評級下調 超重→等重
07/01/2022 422.39% SVB Leerink $21→$7 評級下調 跑贏→市場表現
2022年05月24日 1392.54% 摩根士丹利 $21→$20 維護 超重
2022年05月13日 1467.16% SVB Leerink $22→$21 維護 跑贏大盤
03/23/2022 1467.16% 摩根士丹利 $20→$21 維護 超重
2021年11月12日 1541.79% SVB Leerink $21→$22 維護 跑贏大盤
06/01/2021 2511.94% 摩根士丹利 →$35 開始承保 →超重
06/01/2021 1840.3% 古根海姆 →$26 開始承保 →購買
06/01/2021 2511.94% Evercore ISI集團 →$35 開始承保 →跑贏大盤
06/01/2021 1467.16% SVB Leerink →$21 開始承保 →跑贏大盤

What is the target price for Talaris Therapeutics (TALS)?

Talaris Treeutics(TALS)的目標價格是多少？

The latest price target for Talaris Therapeutics (NASDAQ: TALS) was reported by HC Wainwright & Co. on January 30, 2023. The analyst firm set a price target for $12.00 expecting TALS to rise to within 12 months (a possible 795.52% upside). 10 analyst firms have reported ratings in the last year.

塔拉裡斯治療公司(納斯達克：TALS)的最新目標價是由HC Wainwright&Co.於2023年1月30日報道的。這家分析公司將目標價定為12美元，預計總價值將在12個月內上升(可能上漲795.52%)。去年有10家分析公司公佈了評級。

What is the most recent analyst rating for Talaris Therapeutics (TALS)?

Talaris Treeutics(TALS)的最新分析師評級是什麼？

The latest analyst rating for Talaris Therapeutics (NASDAQ: TALS) was provided by HC Wainwright & Co., and Talaris Therapeutics reiterated their buy rating.

塔拉裡斯治療公司(納斯達克代碼：TALS)的最新分析師評級由HC Wainwright&Co.提供，塔拉裡斯治療公司重申了他們的買入評級。

When is the next analyst rating going to be posted or updated for Talaris Therapeutics (TALS)?

Talaris Treeutics(TALS)的下一次分析師評級將於何時發佈或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Talaris Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Talaris Therapeutics was filed on January 30, 2023 so you should expect the next rating to be made available sometime around January 30, 2024.

分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公共財務報表，與Talaris治療公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Talaris治療公司的上一次評級是在2023年1月30日提交的，所以你應該預計下一次評級將在2024年1月30日左右的某個時候提供。

Is the Analyst Rating Talaris Therapeutics (TALS) correct?

分析師對Talaris Treeutics(TALS)的評級正確嗎？

While ratings are subjective and will change, the latest Talaris Therapeutics (TALS) rating was a reiterated with a price target of $0.00 to $12.00. The current price Talaris Therapeutics (TALS) is trading at is $1.34, which is within the analyst's predicted range.

雖然評級是主觀的，並將發生變化，但最新的Talaris治療(TALS)評級被重申，目標價在0.00美元至12.00美元之間。Talaris Treateutics(TALS)目前的交易價格為1.34美元，在分析師的預測範圍內。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論